Видео ютуба по тегу Peter Hillmen

An interview with Dr. Peter Hillmen - Understanding CLL
An interview with Dr. Peter Hillmen - Understanding CLL
ASM 2018 - Professor Peter Hillmen
ASM 2018 - Professor Peter Hillmen
iwCLL: what to expect
iwCLL: what to expect
Prof Peter Hillmen discusses exciting new data in CLL from EHA19
Prof Peter Hillmen discusses exciting new data in CLL from EHA19
ASH 2019 Interview - Prof Peter Hillmen - Challenges in the CLL/SLL treatment landscape
ASH 2019 Interview - Prof Peter Hillmen - Challenges in the CLL/SLL treatment landscape
prof peter hillmen Leeds part2
prof peter hillmen Leeds part2
Treatment options for patients with CLL who progress after BTK inhibitor therapy
Treatment options for patients with CLL who progress after BTK inhibitor therapy
ASH 2019 Interview - Prof Peter Hillmen - Treatment – patient choice
ASH 2019 Interview - Prof Peter Hillmen - Treatment – patient choice
Peter Hillmen
Peter Hillmen
ASH 2019 Interview - Prof Peter Hillmen - CLL updates from ASH 2019
ASH 2019 Interview - Prof Peter Hillmen - CLL updates from ASH 2019
Peter Hillmen
Peter Hillmen
Peter Hillmen discusses CLL and Covid-19
Peter Hillmen discusses CLL and Covid-19
prof peter hillmen Leeds part1
prof peter hillmen Leeds part1
Future improvements in developing CLL therapy
Future improvements in developing CLL therapy
ASH 2014: Prof John Gribben and Prof Peter Hillmen discuss recent advances in CLL (part 1)
ASH 2014: Prof John Gribben and Prof Peter Hillmen discuss recent advances in CLL (part 1)
Acalabrutinib for the treatment of Richter's transformation and patients with ibrutinib intolerance
Acalabrutinib for the treatment of Richter's transformation and patients with ibrutinib intolerance
Peter Hillmen's Q and A session about CLL
Peter Hillmen's Q and A session about CLL
Do patients with CLL require CAR T-cell therapy?
Do patients with CLL require CAR T-cell therapy?
Peter Hillmen | ASCO 2018 | MRD kinetics for R/R CLL from the phase III MURANO study
Peter Hillmen | ASCO 2018 | MRD kinetics for R/R CLL from the phase III MURANO study
Key MRD monitoring techniques in CLL
Key MRD monitoring techniques in CLL
Prof Peter Hillmen Global Expert explains CLL
Prof Peter Hillmen Global Expert explains CLL
Alternative cellular therapies for patients with CLL
Alternative cellular therapies for patients with CLL
Developments in the use of different classes of BTK inhibitors for CLL treatment
Developments in the use of different classes of BTK inhibitors for CLL treatment
MURANO update: MRD negativity in CLL
MURANO update: MRD negativity in CLL
Part 4 - Q & A - Prof. Peter Hillmen, UK
Part 4 - Q & A - Prof. Peter Hillmen, UK